-
Voice of China POLARIS-03 researched another breakthrough in indigenous immunotherapy: the ORR of PD-L1 positive patients reached 41.7%
Time of Update: 2021-12-07
About 50% of patients respond to platinum-containing therapy, but the response time is short, and the progression-free survival (PFS) is short (7 to 8 months), and the effective rate of second-line single-agent chemotherapy is about 10% .
-
The oncolytic virus CG0070 achieves 100% CR in high-risk bladder cancer patients, and the domestic Lepu Biologics has obtained clinical approval
Time of Update: 2021-12-07
Recently (November 13th, 2021), CG Oncology disclosed the data of its dazzling Phase II clinical trial of its oncolytic virus drug CG0070 combined with K drug .
(CG0070 is the world's first and only oncolytic virus product in the phase III clinical stage for the treatment of NMIBC).
-
A Quick Fact: Perfusion Therapy of Non-muscle Invasive Bladder Cancer
Time of Update: 2021-12-07
Intermediate-risk patients: A single dose of bladder infusion chemotherapy is given immediately after surgery, followed by bladder induction and maintenance infusion, chemotherapy drugs or BCG infusion can be selected, and the infusion time does not exceed 1 year .
-
One-click collection: consensus on the latest guidelines for urinary tumors/urology
Time of Update: 2021-12-06
In view of the current diagnosis and treatment status, combined with clinical practice and related research at home and abroad, the Professional Committee of Urinary and Male Reproductive System Tumors of the Chinese Anti-Cancer Association has formulated the clinic for bone metastasis of prostate cancer and bone-related diseases.
-
2022.V1 NCCN prostate cancer guidelines update: the biggest change in 10 years, active monitoring of low-risk patients deletes "preferred"!
Time of Update: 2021-12-06
Initial treatment and adjuvant treatment for moderate-risk patients with good prognosis (PROS-5) For patients with life expectancy> 10 years, consider definitive prostate biopsy ± mpMRI ± molecular analysis to determine whether it is suitable for active monitoring .
-
EJC What factors affect the OS benefit of enzalutamide in nmCRPC patients?
Time of Update: 2021-12-06
The final analysis of PROSPER showed that compared with only receiving androgen deprivation therapy (ADT), enzalutamide + ADT significantly improved the overall survival of patients with rapidly rising prostate-specific antigen (PSA) and non-metastatic castration-resistant prostate cancer (nmCRPC) Period (OS) .
-
Pure life letter ideas on JAMA Oncology!
Time of Update: 2021-12-05
Here the author uses the Cox proportional hazard model to analyze patients who have received androgen signaling inhibitor (ASI) treatment, and compares the survival between the luminal subtype and the basal subtype .
-
MRI-GB vs TRUS-GB: Who can locate prostate cancer lesions more accurately?
Time of Update: 2021-12-05
Study Introduction This study used a systematic review and meta-analysis to explore three questions: first, whether the detection rate (CDR) of MRI-GB for clinically significant prostate cancer (csPCa) is better than TRUS-GB; second, Whether MRI-GB is better than TRUS-GB in avoiding the detection of PCa that is of no clinical significance; third, among the common MRI-GB strategies, cognitive fusion targeted puncture (COG-TB) and image fusion targeted puncture ( FUS-TB) and In-bore MRI-guided biopsy (IB-TB), which is the better strategy .
-
AAUS Asia Guide: Diagnosis and Treatment of Urinary Tract Infections in Children
Time of Update: 2021-12-05
For patients who are highly sensitive to UTI and have the risk of acquired renal damage (including high-grade VUR, recurrent pyelonephritis, or obvious urinary tract Obstruction) can consider long-term prophylactic use of antibiotics .
-
One article to understand: Prostate tumor-associated antigen T cell targeted therapy
Time of Update: 2021-12-05
Table 2 Clinical studies related to CAR-T and BiTE therapy in prostate cancer.
Due to its high expression and membrane binding properties, PSMA is considered to be an ideal tumor-associated antigen for targeted therapy of prostate cancer .
-
PSMA is unstoppable, fancy playing immunotherapy
Time of Update: 2021-12-05
At present, immunotherapy targeting PSMA has entered the clinic, and it is expected to provide new drug options for patients with advanced castration-resistant prostate cancer in the future .
-
Case analysis: 1 case of special type of cystitis
Time of Update: 2021-12-05
Hydrodilatation treatment under cystoscopy and hyaluronic acid perfusion Water dilatation under sodium and botulinum toxin cystoscopy is not only a common method for diagnosing interstitial cystitis, but also can relieve pain symptoms in some patients through water dilatation .
-
Shanghai Jiaotong University Chen Haige's team published a cover study in the future, only a few milliliters of urine can be used to diagnose bladder cancer non-invasively
Time of Update: 2021-11-16
Recently, the team of Professor Chen Haige from the Department of Urology, Renji Hospital, Shanghai Jiaotong University School of Medicine, published important research results in the form of a cover paper in the famous urology journal "American Journal of Urology", revealing for the first time in the urine specimens of patients with bladder urothelial cancer , Urine tumor DNA (utDNA) exhibits multi-dimensional consistency with tumor DNA (tDNA).
-
China's real-world olaparib research data is released, and clinical efficacy adds more evidence
Time of Update: 2021-11-16
*It is only for medical professionals to read. The research report shows that mCRPC patients in the real world in China can benefit from olaparib treatment. October Nanjing, Dangui Piaoxiang, the 2
-
Heavy release!
Time of Update: 2021-11-15
With the publication of the PROfound data of the Phase III registered clinical study, olaparib has been approved in the United States and China for mCRPC patients with HRR or BRCA gene mutations who have failed a new endocrine therapy, which has changed the treatment of advanced prostate cancer patients.
-
Shanghai Jiaotong University Chen Haige's team has made a big achievement: only a few milliliters of urine can be non-invasive and accurate diagnosis of bladder cancer
Time of Update: 2021-11-15
Recently, Professor Chen Haige's team from the Department of Urology, Renji Hospital, Shanghai Jiaotong University School of Medicine, published an important research result titled: Urinary Molecular Pathology for Patients with Newly Diagnosed Urothelial Bladder Cancer in the Journal of Urology as a cover paper .
-
The role of PSMA PET/CT in clinically limited prostate cancer
Time of Update: 2021-11-15
This article comes from NEJM Journal Watch Evolving Role of PSMA PET/CT in Clinically Localized Prostate Cancer PSMA PET/CT in Clinically Localized Prostate Cancer Comment by Robert Dreicer, MD, MS, MACP, FASCO For intermediate-risk and high-risk prostate cancer patients, PSMA PET/CT may guide treatment decisions for prostatectomy .
-
Professor Ye Dingwei's interpretation of "Expert Consensus on Clinical Diagnosis and Treatment of Bone Metastasis and Bone-related Diseases in Prostate Cancer (2021 Edition)"
Time of Update: 2021-11-15
Despite the continuous improvement of anti-tumor treatment methods, more than 70% of patients with advanced prostate cancer have bone metastases and bone-related events (SREs) caused by bone metabolism disorders, which greatly increases the burden of disease .
-
New endocrine therapy options for patients with prostate cancer and medical complications
Time of Update: 2021-11-15
2. In May 2021, PSA gradually increased, PSMA suggested that more than two metastases appeared, and the patient was diagnosed to enter the stage of castration-resistant prostate cancer (CRPC), and switched to enzalutamide treatment .
-
Professor Ye Dingwei's interpretation of "Secret" by the big coffee "Expert Consensus on the Clinical Diagnosis and Treatment of Bone Metastasis and Bone-Related Diseases of Prostate Cancer (2021 Edition)"
Time of Update: 2021-11-15
Despite the continuous improvement of anti-tumor treatment methods, more than 70% of patients with advanced prostate cancer have bone metastases and bone-related events (SREs) caused by bone metabolism disorders, which greatly increases the burden of disease .
